These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 27259484)

  • 21. Dofetilide reduces the frequency of ventricular arrhythmias and implantable cardioverter defibrillator therapies.
    Baquero GA; Banchs JE; Depalma S; Young SK; Penny-Peterson ED; Samii SM; Wolbrette DL; Naccarelli GV; Gonzalez MD
    J Cardiovasc Electrophysiol; 2012 Mar; 23(3):296-301. PubMed ID: 21955243
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effectiveness of subcutaneous implantable cardioverter-defibrillators and determinants of inappropriate shock delivery.
    Mesquita J; Cavaco D; Ferreira A; Lopes N; Santos PG; Carvalho MS; Haas A; Costa F; Carmo P; Morgado F; Adragão P; Mendes M
    Int J Cardiol; 2017 Apr; 232():176-180. PubMed ID: 28082086
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Very high rate programming in primary prevention patients with reduced ejection fraction implanted with a defibrillator: Results from a large multicenter controlled study.
    Clementy N; Challal F; Marijon E; Boveda S; Defaye P; Leclercq C; Deharo JC; Sadoul N; Klug D; Piot O; Gras D; Bordachar P; Algalarrondo V; Fauchier L; Babuty D;
    Heart Rhythm; 2017 Feb; 14(2):211-217. PubMed ID: 27989789
    [TBL] [Abstract][Full Text] [Related]  

  • 24. SVT discrimination algorithms significantly reduce the rate of inappropriate therapy in the setting of modern-day delayed high-rate detection programming.
    Cheng A; Auricchio A; Schloss EJ; Kurita T; Sterns LD; Gerritse B; Brown ML; Fagan DH; Lexcen DR; Ellenbogen KA
    J Cardiovasc Electrophysiol; 2019 Dec; 30(12):2877-2884. PubMed ID: 31646695
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of a programming algorithm for the third tachycardia zone in a fourth-generation implantable cardioverter-defibrillator.
    Neglia JJ; Krol RB; Giorgberidze I; Mathew P; Lewis C; Munsif AN; Saksena S
    J Interv Card Electrophysiol; 1997 Feb; 1(1):49-56. PubMed ID: 9869951
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ventricular arrhythmia detection for contemporary Biotronik and Abbott implantable cardioverter defibrillators with markedly prolonged detection in Biotronik devices.
    Oesterle A; Dhruva SS; Pellegrini CN; Liem B; Raitt MH
    J Interv Card Electrophysiol; 2023 Oct; 66(7):1679-1691. PubMed ID: 36737506
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-Term Clinical Outcome of Arrhythmogenic Right Ventricular Cardiomyopathy in Individuals With a p.S358L Mutation in TMEM43 Following Implantable Cardioverter Defibrillator Therapy.
    Hodgkinson KA; Howes AJ; Boland P; Shen XS; Stuckless S; Young TL; Curtis F; Collier A; Parfrey PS; Connors SP
    Circ Arrhythm Electrophysiol; 2016 Mar; 9(3):. PubMed ID: 26966288
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel ICD Programming and Inappropriate ICD Therapy in CRT-D Versus ICD Patients: A MADIT-RIT Sub-Study.
    Kutyifa V; Daubert JP; Schuger C; Goldenberg I; Klein H; Aktas MK; McNitt S; Stockburger M; Merkely B; Zareba W; Moss AJ
    Circ Arrhythm Electrophysiol; 2016 Jan; 9(1):e001965. PubMed ID: 26743237
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antitachycardia pacing for very fast ventricular tachycardia and low-energy shock for ventricular arrhythmias in patients with implantable defibrillators.
    Sivagangabalan G; Chik W; Zaman S; Stafford W; Hayes J; Denman R; Young G; Sanders P; Kovoor P
    Am J Cardiol; 2013 Oct; 112(8):1153-7. PubMed ID: 23891430
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of implantable cardiac defibrillators for treatment of ventricular arrhythmias in patients with cardiac sarcoidosis.
    Kron J; Sauer W; Schuller J; Bogun F; Crawford T; Sarsam S; Rosenfeld L; Mitiku TY; Cooper JM; Mehta D; Greenspon AJ; Ortman M; Delurgio DB; Valadri R; Narasimhan C; Swapna N; Singh JP; Danik S; Markowitz SM; Almquist AK; Krahn AD; Wolfe LG; Feinstein S; Ellenbogen KA
    Europace; 2013 Mar; 15(3):347-54. PubMed ID: 23002195
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Syncope in Primary Prevention Implantable Cardioverter Defibrillator Patients.
    Goldenberg G; Bental T; Kadmon U; Zabarsky R; Kusnick J; Barsheshet A; Golovchiner G; Strasberg B
    Isr Med Assoc J; 2016 Jun; 18(6):318-21. PubMed ID: 27468522
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reduction of inappropriate anti-tachycardia pacing therapies and shocks by a novel suite of detection algorithms in heart failure patients with cardiac resynchronization therapy defibrillators: a historical comparison of a prospective database.
    Lunati M; Proclemer A; Boriani G; Landolina M; Locati E; Rordorf R; Daleffe E; Ricci RP; Catanzariti D; Tomasi L; Gulizia M; Baccillieri MS; Molon G; Gasparini M;
    Europace; 2016 Sep; 18(9):1391-8. PubMed ID: 26826135
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Influence of diabetes mellitus on inappropriate and appropriate implantable cardioverter-defibrillator therapy and mortality in the Multicenter Automatic Defibrillator Implantation Trial-Reduce Inappropriate Therapy (MADIT-RIT) Trial.
    Ruwald MH; Zareba W; Jons C; Zhang C; Ruwald AC; Olshansky B; McNitt S; Bloch Thomsen PE; Shoda M; Merkely B; Moss AJ; Kutyifa V
    Circulation; 2013 Aug; 128(7):694-701. PubMed ID: 23881862
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Arrhythmia rate distribution and tachyarrhythmia therapy in an ICD population: results from the INTRINSIC RV trial.
    Sullivan RM; Russo AM; Berg KC; Stolen KQ; Seth M; Perschbacher D; Day JD; Olshansky B
    Heart Rhythm; 2012 Mar; 9(3):351-8. PubMed ID: 22016074
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term follow-up of patients with cardiac sarcoidosis and implantable cardioverter-defibrillators.
    Betensky BP; Tschabrunn CM; Zado ES; Goldberg LR; Marchlinski FE; Garcia FC; Cooper JM
    Heart Rhythm; 2012 Jun; 9(6):884-91. PubMed ID: 22338670
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical relevance of slow ventricular tachycardia in heart failure patients with primary prophylactic implantable cardioverter defibrillator indication.
    Lüsebrink U; Duncker D; Hess M; Heinrichs I; Gardiwal A; Oswald H; König T; Klein G
    Europace; 2013 Jun; 15(6):820-6. PubMed ID: 23325044
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Benefit of the Wearable Cardioverter-Defibrillator in Protecting Patients After Implantable-Cardioverter Defibrillator Explant: Results From the National Registry.
    Ellenbogen KA; Koneru JN; Sharma PS; Deshpande S; Wan C; Szymkiewicz SJ
    JACC Clin Electrophysiol; 2017 Mar; 3(3):243-250. PubMed ID: 29759518
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Outcomes of defibrillator therapy in catecholaminergic polymorphic ventricular tachycardia.
    Roses-Noguer F; Jarman JW; Clague JR; Till J
    Heart Rhythm; 2014 Jan; 11(1):58-66. PubMed ID: 24120999
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of a discrimination algorithm to reduce inappropriate shocks with a subcutaneous implantable cardioverter-defibrillator.
    Gold MR; Weiss R; Theuns DA; Smith W; Leon A; Knight BP; Carter N; Husby M; Burke MC
    Heart Rhythm; 2014 Aug; 11(8):1352-8. PubMed ID: 24732366
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risk of subsequent ventricular arrhythmia is higher in primary prevention patients with implantable cardioverter defibrillator than in secondary prevention patients.
    Zhou Y; Zhao S; Chen K; Hua W; Su Y; Chen S; Liang Z; Xu W; Zhang S
    BMC Cardiovasc Disord; 2019 Oct; 19(1):230. PubMed ID: 31638918
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.